Andrea Cercek1, Jinru Shia2, Marc Gollub3, Joanne F Chou4, Marinela Capanu4, Pamela Raasch5, Diane Reidy-Lagunes5, David A Proia6, Efsevia Vakiani2, David B Solit5, Leonard B Saltz5. 1. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: cerceka@mskcc.org. 2. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY. 3. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY. 4. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY. 5. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. 6. Synta Pharmaceuticals Corp, Lexington, MA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
Abstract
BACKGROUND: Heat shock protein 90 (Hsp90) is a cellular chaperone that is required for the maturation and stability of a variety of proteins that play key roles in colon cancer initiation and progression. The primary objective of the current study was to define the safety and efficacy of ganetespib, a novel, selective small-molecule Hsp90 inhibitor, in patients with refractory metastatic colorectal cancer. PATIENTS AND METHODS: The study was a single-arm, Simon 2-stage, phase II trial for patients with chemotherapy-refractory, metastatic colorectal cancer. Patients received ganetespib 200 mg/m(2) intravenously. Tumor tissue was collected before treatment and 48 hours after treatment for changes in expression of Hsp90 client proteins and other potential pharmacodynamics markers. V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B, and phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutational status was also determined. RESULTS: Seventeen patients were treated (median age, 58; range, 44-79 years). No patients demonstrated objective regression of disease. Two patients had stable disease of 6.8 and 5.1 months duration. Serious adverse events that were potentially attributable to ganetespib included diarrhea (12%, n = 2), fatigue (17%, n = 3), and increased aspartate aminotransferase/alanine aminotransferase (12%, n = 2) and alkaline phosphatase (6%, n = 1) levels. Of the 17 evaluable patients, 9 (53%) including patients with stable disease as best response, had KRAS-mutant tumors. CONCLUSION: In this first phase II investigation of an Hsp90 inhibitor in colorectal cancer, ganetespib as a single agent did not demonstrate activity in chemotherapy-refractory metastatic colorectal cancer. However, on the basis of the drug's promising preclinical combination data and the relatively mild toxicity profile, further clinical investigation of this agent in combination with standard cytotoxic agents is planned.
BACKGROUND:Heat shock protein 90 (Hsp90) is a cellular chaperone that is required for the maturation and stability of a variety of proteins that play key roles in colon cancer initiation and progression. The primary objective of the current study was to define the safety and efficacy of ganetespib, a novel, selective small-molecule Hsp90 inhibitor, in patients with refractory metastatic colorectal cancer. PATIENTS AND METHODS: The study was a single-arm, Simon 2-stage, phase II trial for patients with chemotherapy-refractory, metastatic colorectal cancer. Patients received ganetespib 200 mg/m(2) intravenously. Tumor tissue was collected before treatment and 48 hours after treatment for changes in expression of Hsp90 client proteins and other potential pharmacodynamics markers. V-Ki-ras2 Kirsten ratsarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B, and phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutational status was also determined. RESULTS: Seventeen patients were treated (median age, 58; range, 44-79 years). No patients demonstrated objective regression of disease. Two patients had stable disease of 6.8 and 5.1 months duration. Serious adverse events that were potentially attributable to ganetespib included diarrhea (12%, n = 2), fatigue (17%, n = 3), and increased aspartate aminotransferase/alanine aminotransferase (12%, n = 2) and alkaline phosphatase (6%, n = 1) levels. Of the 17 evaluable patients, 9 (53%) including patients with stable disease as best response, had KRAS-mutant tumors. CONCLUSION: In this first phase II investigation of an Hsp90 inhibitor in colorectal cancer, ganetespib as a single agent did not demonstrate activity in chemotherapy-refractory metastatic colorectal cancer. However, on the basis of the drug's promising preclinical combination data and the relatively mild toxicity profile, further clinical investigation of this agent in combination with standard cytotoxic agents is planned.
Authors: Nathan T Ihle; Lauren A Byers; Edward S Kim; Pierre Saintigny; J Jack Lee; George R Blumenschein; Anne Tsao; Suyu Liu; Jill E Larsen; Jing Wang; Lixia Diao; Kevin R Coombes; Lu Chen; Shuxing Zhang; Mena F Abdelmelek; Ximing Tang; Vassiliki Papadimitrakopoulou; John D Minna; Scott M Lippman; Waun K Hong; Roy S Herbst; Ignacio I Wistuba; John V Heymach; Garth Powis Journal: J Natl Cancer Inst Date: 2012-01-13 Impact factor: 13.506
Authors: F Perrone; A Lampis; M Orsenigo; M Di Bartolomeo; A Gevorgyan; M Losa; M Frattini; C Riva; S Andreola; E Bajetta; L Bertario; E Leo; M A Pierotti; S Pilotti Journal: Ann Oncol Date: 2008-07-31 Impact factor: 32.976
Authors: Jeffrey Cummings; Brian T Ethell; Lesley Jardine; Gary Boyd; Janet S Macpherson; Brian Burchell; John F Smyth; Duncan I Jodrell Journal: Cancer Res Date: 2003-12-01 Impact factor: 12.701
Authors: Christine A Pratilas; Aphrothiti J Hanrahan; Ensar Halilovic; Yogindra Persaud; Junichi Soh; Dhananjay Chitale; Hisayuki Shigematsu; Hiromasa Yamamoto; Ayana Sawai; Manickam Janakiraman; Barry S Taylor; William Pao; Shinichi Toyooka; Marc Ladanyi; Adi Gazdar; Neal Rosen; David B Solit Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701
Authors: Cheryl A London; Jaime Acquaviva; Donald L Smith; Manuel Sequeira; Luisa Shin Ogawa; Heather L Gardner; Louis Feo Bernabe; Misty D Bear; Sandra A Bechtel; David A Proia Journal: Clin Cancer Res Date: 2018-08-31 Impact factor: 12.531
Authors: Anna V Kudryavtseva; Anastasia V Lipatova; Andrew R Zaretsky; Alexey A Moskalev; Maria S Fedorova; Anastasiya S Rasskazova; Galina A Shibukhova; Anastasiya V Snezhkina; Andrey D Kaprin; Boris Y Alekseev; Alexey A Dmitriev; George S Krasnov Journal: Oncotarget Date: 2016-08-16
Authors: Ryan C Chai; Jessica L Vieusseux; Benjamin J Lang; Chau H Nguyen; Michelle M Kouspou; Kara L Britt; John T Price Journal: Mol Oncol Date: 2017-04-11 Impact factor: 6.603
Authors: Sheah Lin Lee; Nina Claire Dempsey-Hibbert; Dale Vimalachandran; Terence David Wardle; Paul A Sutton; John H H Williams Journal: Cell Stress Chaperones Date: 2017-03-02 Impact factor: 3.667